Jason Romancik, MD

Articles by Jason Romancik, MD

Dr. Romancik on Maximizing CAR T-cell Therapy in NHL

ByJason Romancik, MD

December 8th 2022

Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Romancik on the Benefit of Second-line Axi-cel in R/R DLBCL

ByJason Romancik, MD

November 17th 2022

Jason Romancik, MD, discusses the benefit of axicabtagene ciloleucel vs standard of care as a second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.

Jason Romancik, MD, of Winship Cancer Institute, Emory University

Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL

ByJason Romancik, MD

November 1st 2022

Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.

Jason Romancik, MD

Articles by Jason Romancik, MD

Dr. Romancik on Maximizing CAR T-cell Therapy in NHL

Dr. Romancik on the Benefit of Second-line Axi-cel in R/R DLBCL

Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Oncology Fellows Highlights 2025 ESMO Fellowship Winners